50% off Premium Yearly

NASDAQ:GMAB
This summary was created by AI, based on 3 opinions in the last 12 months.
Genmab ADR (GMAB-Q) is a biotech company based in the Netherlands focused on creating human antibody treatments for cancer. Recent earnings reports show a significant 19% revenue increase, driven largely by a remarkable 54% boost in sales from proprietary cancer treatments. Despite the fluctuation in stock performance, experts have varying views; some recommend covering positions due to a recent downturn, highlighting a 17% total loss from prior investments, while others urge to maintain the stock as a top pick based on solid fundamentals. The company enjoys robust cash reserves and is actively reducing its debt, largely due to a lucrative royalty agreement with Johnson & Johnson. Analysts forecast strong EPS growth and suggest a potential upside in the stock's price, continuing to endorse a protective stop-loss strategy at $24, targeting prices around $37.
Genmab ADR is a American stock, trading under the symbol GMAB (previously GMAB-Q on Stockchase) on the NASDAQ (GMAB). It is usually referred to as NASDAQ:GMAB or GMAB
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on GMAB (previously GMAB-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Genmab ADR.
Genmab ADR was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-02-12. Read the latest stock experts ratings for Genmab ADR.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Genmab ADR.
Genmab ADR is covered by Stockchase experts and is worth watching.
On 2026-06-22, Genmab ADR (GMAB) stock closed at a price of $25.61.
Our PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.